EVgo (EVGO) Gets a Buy from Evercore ISI
Confident Investing Starts Here:
According to TipRanks, West is ranked #9438 out of 9595 analysts.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for EVgo with a $5.86 average price target, a 29.65% upside from current levels. In a report released yesterday, UBS also reiterated a Buy rating on the stock with a $5.00 price target.
Based on EVgo's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $75.29 million and a GAAP net loss of $26.05 million. In comparison, last year the company earned a revenue of $55.16 million and had a GAAP net loss of $9.77 million
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EVGO in relation to earlier this year. Last month, DENNIS G KISH, the President of EVGO sold 120,000.00 shares for a total of $444,874.95.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
7 hours ago
- Bloomberg
Bloomberg Balance of Power: Trump Sets New Tariffs
Watch Joe and Kailey LIVE every day on YouTube: Bloomberg Washington Correspondents Joe Mathieu and Kailey Leinz deliver insight and analysis on the latest headlines from the White House and Capitol Hill, including conversations with influential lawmakers and key figures in politics and policy. President Donald Trump unveiled the first in a wave of promised letters that threaten to impose higher tariffs rates on key trading partners, including levies of 25% on goods from Japan and South Korea beginning Aug. 1. Trump also announced 25% rates on Malaysia and Kazakhstan, while South Africa would see a 30% tariff and Laos and Myanmar would face a 40% levy. The nations were the first in what the president promised would be a flurry of unilateral warnings and trade deals announced on Monday, two days before agreements are due from trading partners facing his April 2 so-called reciprocal levies. 'Our relationship has been, unfortunately, far from Reciprocal,' Trump wrote in the letters. On this edition of Balance of Power, Joe and Kailey speak with: Tyler Kendall, Bloomberg Washington correspondent Sarah Bianchi, senior managing director and chief strategist of international political affairs and public policy at Evercore ISI/Former-Deputy U.S. Trade Representative Julie Fine, Bloomberg Dallas bureau chief Rick Davis, Partner at Stonecourt Capital and Bloomberg Politics Contributor & Jeanne Sheehan Zaino, Senior Democracy Fellow with the Center for the Study of the Presidency & Congress and Bloomberg Politics Contributor Natasha Hall, Non-Resident Senior Associate, Geopolitics and Foreign Policy Department at the Center for Strategic & International Studies
Bloomberg
9 hours ago
- Bloomberg
Evercore ISI's Sarah Bianchi on Global Trade Uncertainty
Evercore ISI Head of US Public Policy & Political Strategy Research, and Former Deputy US Trade Representative Sarah Bianchi outlines the impacts of President Trump's tariffs on Japan and South Korea, as well as the impacts it might have on other nations. (Source: Bloomberg)
Business Wire
10 hours ago
- Business Wire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of West Pharmaceuticals
NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against West Pharmaceutical Services, Inc. ('West' or the 'Company') (NYSE: WST) and reminds investors of the July 7, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements Share Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (a) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin High-Value Products portfolio; (b) West's SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to the Company's profit margins due to operational inefficiencies; (c) these margin pressures created the risk of costly restructuring activities, including the Company's exit from continuous glucose monitoring contracts with long-standing customers; and (d) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis. The truth about this fraud was revealed over a series of disclosures culminating on February 13, 2025, when West issued extremely weak 2025 revenue and earnings forecasts. West attributed the disappointing guidance in part to contract manufacturing headwinds, including the loss of two major continuing glucose monitoring customers that had begun transitioning to in-house manufacturing of next-generation devices after West 'made the decision to not participate going forward as our financial thresholds cannot be achieved.' West also revealed that its SmartDose wearable injector devices would be 'margin-dilutive' in 2025 and that it would be 'taking steps to improve [its SmartDose] economics, and all options are on the table.' On this news, West's stock dropped $123.17 per share, a decline of 38 percent, to close at $199.11 on February 13, 2025. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding West's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the West Pharmaceutical Services class action, go to or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Follow us for updates on LinkedIn, on X, or on Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
